FDA user fees
Executive Summary
The Natl. Assn. of Pharmaceutical Mfrs. requested in an Aug. 20 letter to FDA that the agency provide a 60 day comment period on its proposal for user fees, published in the Aug. Federa/Register ("The Pink Sheet" Aug. 12, p. 8). NAPM also said FDA should hold a regulatory hearing on the issue.
You may also be interested in...
Creating Healthcare Unicorns: Ex-Novartis CFO Shares Secret Sauce
Ex-Novartis executive and co-founder of investment bank MM Dillon & Co shares insights around where healthcare unicorns can be found and some core criteria to build such firms.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast edition of Scrip's Five Must-Know Things, hear about Sanofi’s rebates, Moderna’s business prospects, US views on coronavirus vaccine comparisons, Piot talk about virus variants, and new results for Amgen's asthma drug.
QUOTED. 8 March 2021. Martin Stürmer.
Right now, it appears that COVID-19 diagnostics are holding up against new variants of the virus being detected, but that may not always be the case scientists said at a recent webinar organized by Agena Bioscience. See what Martin Stürmer, laboratory head of IMD Labor in Frankfurt Germany, said about it here.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: